Search Results - guang+wong

3 Results

Sort By:

Recombinant CTRP3 as Protein Therapeutics for Non-alcoholic Fatty Liver Disease (NAFLD)

Non-alcoholic fatty liver disease (NAFLD), a major cause of liver dysfunction, is characterized by intrahepatic triacylglycerol (TAG) overaccumulation resulting from excess dietary lipids and de novo fatty acid synthesis. NAFLD is closely linked to insulin resistance and uncontrolled gluconeogenesis and, hence, is often associated with obesity. Yet,...

Published: 3/13/2025 | Inventor(s): Jonathan Peterson, Guang Wong

Keywords(s): Biologics, Disease Indication, Liver Disorders, Protein, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Hepatology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities

Use of C1q/TNF-related Protein-1 (CTRP1) to Treat Fatty Liver Disease (steatosis)

Unmet NeedObesity is a leading preventable cause of death worldwide, and it is associated with a number of comorbidities, including Non-alcoholic Fatty Liver Disease (NAFLD). Fatty liver is the accumulation of triglycerides and other fats in the liver cells. The amount of fatty acid in the liver depends on the balance between the processes of delivery...

Published: 3/13/2025 | Inventor(s): Guang Wong, Susana Rodriguez

Keywords(s): Biologics, Disease Indication, Metabolic Disorders, Natural compounds, Non-novel, Predicted Novelty, Protein, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Metabolic Diseases, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities

Novel Protein Therapeutic for Diabetes and Obesity

Novelty: This technology identifies a novel myonectin protein, which links skeletal muscle to metabolic regulation. Myonectin was found to lower circulating free fatty acid levels by promoting lipid uptake. Value Proposition: Type-2 diabetes, obesity, and metabolic syndrome are diseases that dramatically reduce patient quality of life and lead...

Published: 3/13/2025 | Inventor(s): Marcus Seldin, Guang Wong

Keywords(s): Biomarker, Diabetes, Disease Indication, Mechanism-of-action Biomarker, Metabolic Disorders, Obesity, Therapeutic Matter, Therapeutics, Type II Diabetes

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Metabolic Diseases, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Metabolic Diseases > Obesity, Clinical and Disease Specializations > Diabetes > Type 2 Diabetes